Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial.

Vesna Lukenda ZankoViktor DomislovicVladimir TrkuljaIrena Krznaric-ZrnicTamara Turk-WensveenZeljko KrznaricTajana Filipec KanizajDelfa Radic-KristoLidija Bilic-ZulleLidija OrlicPetra Dinjar-KujundzicGoran PoropatDavor StimacGoran HauserIvana Mikolasevic

Published in: Diabetes, obesity & metabolism (2020)

Low-medium dose supplementation of vitamin D (1000 IU/day) over 12 months reduces TE indices of liver steatosis (CAP) and fibrosis (LSM) in NAFLD patients.

Keyphrases

double blind
end stage renal disease
newly diagnosed
liver fibrosis
ejection fraction
chronic kidney disease
clinical trial
insulin resistance
prognostic factors
study protocol
peritoneal dialysis
type diabetes
randomized controlled trial
adipose tissue
skeletal muscle
subarachnoid hemorrhage
phase ii